Isoniazid News and Research

RSS

Regular, low-cost preventive medication can protect people with HIV from TB

Children and adults living with HIV can be protected from one of their deadliest threats - tuberculosis (TB) - with a regular, low-cost preventive medication according to new guidelines launched today by the WHO. Of the nearly two million AIDS-related deaths each year, a quarter of them are associated with TB.

2 Dec 2010

Immunitor completes V5 Phase IIb imm01 clinical trial enrollment for TB

Immune Network Ltd., advises that its potential acquisition, Immunitor USA Inc., has announced the completion of enrollment in its Phase IIb imm01 clinical trial of V5 in tuberculosis.

15 Nov 2010

Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA

Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of life-threatening infectious diseases, announced it has signed an agreement with the Ludwig-Maximilians-University (LMU) of Munich to coordinate a European Union grant for Phase 2 clinical trials of SQ109 in adult pulmonary tuberculosis (TB) in seven sites in Africa.

18 Oct 2010

Philippine FDA's LSD attains ISO/IEC 17025:2005 accreditation for testing and calibration laboratories

In an effort that will contribute to raising the quality of medicines in the Philippines and surrounding regions, the Laboratory Services Division (LSD) of the Philippine Food and Drug Administration (FDA) has attained the internationally recognized accreditation for testing and calibration laboratories, International Organization for Standardization/ International Electrotechnical Commission (ISO/IEC) 17025:2005.

13 Jul 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Scientists awarded $3.9M grant to study how XDR-TB transmitted in rural South Africa

The National Institutes of Health has awarded scientists at Albert Einstein College of Medicine of Yeshiva University a five-year, $3.9 million grant to study how extensively drug-resistant tuberculosis is transmitted in rural South Africa. The findings could alter public health approaches for controlling the XDR-TB epidemic in the developing world.

3 Jun 2010

Recent releases in Global Health

A Lancet Infectious Diseases Leading Edge article examines the history of the global efforts to control polio and the challenges associated with targets to globally eradicate the disease. "The eradication of polio seems imminent, but with so few cases, there is a temptation to think an acceptable level of infection has been achieved. Not so.

29 May 2010

Research challenges current thinking about TB bacterium

Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.

30 Mar 2010

New WHO report estimates 440,000 MDR-TB cases worldwide in 2008

There were an estimated 440,000 cases of multidrug-resistant tuberculosis (MDR-TB) around the world in 2008 - one-third of which were fatal, according to a new WHO report on drug-resistant TB, the Los Angeles Times reports (Maugh, 3/19).

20 Mar 2010

WHO estimates 440 000 MDR-TB cases in 2008

In some areas of the world, one in four people with tuberculosis (TB) becomes ill with a form of the disease that can no longer be treated with standard drugs regimens, a World Health Organization (WHO) report says.

19 Mar 2010

Rifampicin resistant tuberculosis

Scientists have identified a strain of antibiotic-resistant tuberculosis that thrives in the presence of rifampin, a front-line drug in the treatment of tuberculosis. The bacterium was identified in a patient in China and is described in a study by researchers at the Johns Hopkins Bloomberg School of Public Health, Chongqing Pulmonary Hospital, Lanzhou University and Fudan University.

22 Dec 2009

Researchers validate a technique capable of quick TB diagnosis

The team headed by Doctor Manuel Casal, head of Microbiology at Reina Sofia Hospital in Cordoba has validated in patients a technique, originally produced by a German company, capable of diagnosing tuberculosis in only one day and determining whether or not it is resistant to two of the drugs used to treat this disease.

7 Oct 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

Lancet Infectious Diseases examines spread of XDR-TB

The journal Lancet Infectious Diseases examines the worldwide spread of extensively drug-resistant tuberculosis (XDR-TB). Currently, about 500,000 of the 9 million new cases of TB that are identified each year are strains of XDR-TB. "Drug resistance is largely man-made - it is vitally important to review antibiotic treatment strategies and to ensure the Stop TB Strategy is fully applied to prevent further selection of drug-resistant mutants," Leonard Amaral of Universidade Nova de Lisboa said.

24 Jun 2009

Slow-growing tuberculosis bacteria point the way to new drug development

The discovery of a large number of slow-growing Mycobacterium tuberculosis bacteria, which cause tuberculosis (TB), in the lungs of TB patients could be an important step forward in the design of new anti-TB drugs.

30 Mar 2009

Canadian researchers to launch clinical trial to determine efficacy of treating latent TB with four-month course of Rifampin

Researchers at McGill University in Montreal on Tuesday announced they will soon launch an international clinical trial to determine if latent tuberculosis can be treated successfully with a four-month treatment course of the TB drug rifampin rather than the standard nine-month treatment with the TB drug isoniazid, the CP/Toronto Sun reports.

24 Mar 2009

Doctors call for change in how non-active tuberculosis in immigrant children treated

New guidelines proposed in the March 2009 issue of the journal Pediatrics by researchers from the Indiana University School of Medicine and Riley Hospital for Children may have a major impact on how pediatricians and family physicians treat non-active tuberculosis (TB) in children who are immigrants, internationally adopted or refugees.

2 Mar 2009

Drug combo shows potential for treating extensively drug resistant tuberculosis

A combination of two FDA-approved drugs, already approved for fighting other bacterial infections, shows potential for treating extensively drug resistant tuberculosis (XDR-TB), the most deadly form of the infection.

26 Feb 2009

New treatment for latent form of tuberculosis

Patients who are infected with the latent form of tuberculosis (TB) show no symptoms and are not contagious, yet they pose the biggest challenge when it comes to controlling the disease.

23 Jan 2009